Systematic review of the evidence base for the medical treatment of paediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 50, Issue SUPPL. 1, 2010, Pages

  Wilson, D C ^a   Thomas, A G ^b   Croft, N M ^c   Newby, E ^d   Akobeng, A K ^b   Sawczenko, A ^e   Fell, J M E ^f   Murphy, M S ^g   Beattie, R M ^h   Sandhu, B K ⁱ   Mitton, S G ^j  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b BOOTH HALL CHILDREN S HOSPITAL   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Countess of Chester Hospital ^*  (United Kingdom)

^e HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^f CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

ⁱ Royal Hospital for Children   (United Kingdom)

^j ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; CD25 ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; FISH OIL; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; OLSALAZINE; PLACEBO; PREDNISOLONE; PREDNISONE; PROBIOTIC AGENT; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CATARACT; CHILDHOOD DISEASE; COLON RESECTION; CROHN DISEASE; DATA BASE; DRUG HYPERSENSITIVITY; DRUG SYNTHESIS; DRUG WITHDRAWAL; ENTERIC FEEDING; ENTERITIS; EVIDENCE BASED MEDICINE; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; INTRACRANIAL HYPERTENSION; INTRAOCULAR PRESSURE; LOW DRUG DOSE; METHODOLOGY; MOOD CHANGE; PANCREATITIS; PARENTERAL NUTRITION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; SIDE EFFECT; SYSTEMATIC REVIEW; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BONE AND BONES; CHILD; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MAINTENANCE CHEMOTHERAPY; MESALAMINE; REMISSION INDUCTION; SULFASALAZINE;

EID: 77956917103     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181c92caa     Document Type: Article

References (151)

1. Griffiths AM, Hugot J-P. Crohn disease. In: Walker WA, Goulet O, Kleinman RE (eds). Pediatric Gastrointestinal Disease. 4th ed.et al. Hamilton, Canada: BC Decker; 2004. pp. 789-824.
2. Leichtner AM, Higuchi L. Ulcerative colitis. In: Walker WA, Goulet O, Kleinman RE (eds). Pediatric Gastrointestinal Disease. 4th ed.et al. Hamilton, Canada: BC Decker; 2004. pp. 825-49.
3. Armitage E, Drummond HE,Wilson DC, et al. Increasing incidence of both juvenile-onset Crohn's disease and ulcerative disease in Scotland. Eur J Gastroenterol Hepatol 2001;13:1439-47.
4. Sawczenko A, Lynn R, Sandhu BK. Variations in initial assessment and management of inflammatory bowel disease across Great Britain and Ireland. Arch Dis Child 2003;88:990-4.
5. Escher JC, Taminiau JAJM, Niuwenhuis EES, et al. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003;9:34-58.
6. Beattie RM, Croft NM, Fell JM, et al. Inflammatory Bowel Disease. Arch Dis Child 2006;91:426-32.
7. Bremner AR, Griffiths DM, Beattie RM. Current therapy of ulcerative colitis in children. Expert Opin Pharmacother 2004;5:37-53.
8. Bremner AR, Beattie RM. Therapy of Crohn's disease in childhood. Expert Opin Pharmacother 2002;3:809-25.
9. Stange EF, Travis SPL, Vermiere S, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006;55 (Suppl 1):i1-5.
10. Travis SPL, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 2006;55 (Suppl 1):i16-35.
11. Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006;55 (Suppl 1):i36-58.
12. Carter MJ, Lobo AJ, Travis SBL, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004;53 (Suppl V): V1-V16.
13. The AGREE Collaboration. Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument. www.agreecollaboration.org . Accessed November 10, 2009.
14. SIGN 50. A Guideline Developer's Handbook. Scottish Intercollegiate Guidelines Network. www.sign.ac.uk. Accessed November 10, 2009.
15. Harbour R, Miller J. A new system for recommendations in evidence based guidelines. BMJ 2001;323:334-6.
16. Tomomasa T, Kobayashi A, Ushijima K, et al. Guidelines for treatment of ulcerative colitis in children. Pediatr Int 2004;46:494-6.
17. Working Group of the Japanese Society for Paediatric Gastroenterology, Hepatology and Nutrition. Guidelines for the treatment of Crohn's disease in children. Pediatr Int 2006; 48:349-52.
18. Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
19. Jaspers GJ, Verhade HJ, Escher JC, et al. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis 2006;12:831-6.
20. Markowitz J, Grancher K, Mandel F, et al. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum. Am J Gastroenterol 1993;88:44-8.
21. Markowitz J, Grancher K, Kohn N, et al. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol 2002;97:928-32.
22. Casson DH, Davies SE, Thomson MA, et al. Low-dose intravenous azathioprine may be effective in the management of acute fulminant colitis complicating inflammatory bowel disease. Aliment Pharmacol Ther 1999;13:891-5.
23. Papp JP, Watson DW, Bull FE. Azathioprine treatment in Crohn's disease. Am J Gastroenterol 1974;61:136-42.
24. Kader HA, Mascarenhas MR, Piccoli DA, et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999;28:54-8.
25. Markowitz J, Rosa J, Grancher K, et al. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99:1347-51.
26. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990;117:809-14.
27. Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000;30:294-8.
28. Fuentes D, Torrente F, Keady S, et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther 2003;17:913-21.
29. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813-21.
30. Barnes BH, Borowitz SM, Saulsbury FT, et al. Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. J Pediatr Gastroenterol Nutr 2004;38:509-12.
31. Treem WR, Cohen J, Davis PM, et al. Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results, and impact on surgery. Dis Colon Rectum 1995;38:474-9.
32. Benkov KJ, Rosh JR, Schwersenz AH, et al. Cyclosporine as an alternative to surgery in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1994;19:290-4.
33. Mahdi G, Israel DM, Hassall E. Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children. Am J Gastroenterol 1996;91:1355-9.
34. Hyams JS, Treem WR. Cyclosporine treatment of fulminant colitis. J Pediatr Gastrenterol Nutr 1989;9:383-7.
35. Nicholls S, Domizio P, Williams CB, et al. Cyclosporin as initial treatment of Crohn's disease. Arch Dis Child 1994;71:243-7.
36. Ramakrishna J, Langhans N, Calenda K, et al. Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1996;22: 296-302.
37. Casson DH, Eltumi M, Tomlin S, et al. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000;47:436-40.
38. Russell RK, Richardson N, Wilson DC. Systemic absorption with complications during topical tacrolimus treatment for orofacial Crohn disease. J Pediatr Gastroenterol Nutr 2001;32:207-8.
39. Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000;137:794-9.
40. Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998;132:830-5.
41. Uhlen S, Belbouab R, Narebski K, et al. Efficacy of methotrexate in pediatric Crohn's disease: A French multicenter study. Inflamm Bowel Dis 2006;12:1053-7.
42. Facchini S, Candusso M, Martelossi S, et al. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J Pediatr Gastroenterol Nutr 2001;32:178-81.
43. Odeka EB, Miller V. Thalidomide in oral Crohn's disease refractory to conventional medical treatment. J Pediatr Gastroenterol Nutr 1997;25: 250-1.
44. Griffiths A, Koletzko S, Sylvester F, et al. Slow-release 5-aminosalicylic acid therapy in children with small intestinal Crohn's disease. J Pediatr Gastroenterol Nutr 1993;17:186-92.
45. Ferry GD, Kirschner BS, Grand RJ, et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group clinical trial. J Pediatr Gastroenterol Nutr 1993;17:32-8.
46. Odera G, Giuliani B, Santini B, et al. Topical treatment with 5-ASA and hydrocortisone. Riv Ital Pediatr 1986;12:674-8.
47. D'Agata I, Vanounou T, Seidman E. Mesalamine in paediatric inflammatory bowel disease: A 10-year experience. Inflamm Bowel Dis 1996;2:229-35.
48. Christensen LA, Fallingborg J, Jacobsen BA, et al. Bioavailability of 5-aminosalicyclic acid from slow release 5-aminosalicyclic acid drug and sulfasalazine in normal children. Dig Dis Sci 1993;38: 1831-6.
49. Barden L, Lipson A, Pert P, et al. Mesalazine in childhood inflammatory bowel disease. Aliment Pharmacol Ther 1989;3:597-603.
50. Bondesen S, Nielsen OH, Schou JB, et al. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis. Scand J Gastroenterol 1986;21:693-700.
51. Clarke DF, George D, Milsap RL, et al. Sulfasalazine pharmacokinetics in children. Pediatr Pharmacol 1982;2:323-33.
52. Leickly FE, Buckley RH. Development of IgA and IgG2 subclass deficiency after sulfasalazine therapy. J Pediatr 1986;108:481-2.
53. Tolia V, Massoud N, Klotz U. Oral 5-aminosalicyclic acid in children with colonic chronic inflammatory bowel disease: clinical and pharmacokinetic experience. J Pediatr Gastroenterol Nutr 1989;8:333-8.
54. Goldstein F, Farquhar S, Thornton JJ, et al. Favorable effects of sulfasalazine on small bowel Crohn's disease: a long-term study. Am J Gastroenterol 1987;82:848-53.
55. Koutras A, Daum F, Das KM, et al. Sulfasalazine and renal tubular function: lack of an effect. J Pediatr Gastroenterol Nutr 1985;4:103-6.
56. Wiersma H, Escher JC, Dilger K, et al. Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:626-31.
57. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53.
58. Sanderson IR, Udeen S, Davies PS, et al. Remission induced by an elemental diet in small bowel Crohn's disease. Arch Dis Child 1987;62:123-7.
59. Ruuska T, Savilahte E, Maki M, et al. Exclusive whole protein enteral diet versus prednisolone in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 1994;19:175-80.
60. Thomas AG, Taylor F, Miller V. Dietary intake and nutritional treatment in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 1993;17:75-81.
61. Levine A, Weizman Z, Broide E, et al. A comparison of budesonide and prednisolone for the treatment of active paediatric Crohn's disease. J Pediatr Gastroenterol Nutr 2003;36:248-52.
62. Escher JC. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double blind, controlled, multicentre trial. Eur J Gastroenterol Hepatol 2004;16:47-54.
63. Heuschkel RB, Menacne CC, Megerian JT, et al. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000;31:8-15.
64. Hyams J, Markowitz J, Lerer T, et al. The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol Hepatol 2006;4:1118-23.
65. Markowitz J, Hyams J, Mack D, et al. Corticosteroid therapy in the age of infliximab: acute and 1-year outcomes in newly diagnosed children with Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1124-9.
66. Tung J, Loftus EV, Freese DK, et al. A population based study of the frequency of corticosteroid dependence and resistance in paediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006;12:1093-100.
67. Kundhal P, Zachos M, Holmes JL, et al. Controlled ileal release budesonide in pediatric Crohn disease: efficacy and effect on growth. J Pediatr Gastroenterol Nutr 2001;33:75-80.
68. Levine A, Broide E, Stein M, et al. Evaluation of oral budesonide for treatment of mild and moderate exacerbations of Crohn's disease in children. J Pediatr 2002;140:75-80.
69. Lundi PD, Edsbacker S, Bergstrand M, et al. Pharmacokinetics of budesonide controlled ileal release capsules in children and adults with active Crohn's disease. Aliment Pharmacol Ther 2003;17:85-92.
70. Dilger K, Alberer M, Busch A, et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment Pharmacol Ther 2006;23:387-96.
71. Papadopoulou A, Rawashdeh MO, Brown GA, et al. Remission following an elemental diet or prednisolone in Crohn's disease. Acta Paediatr 1995;84:79-83.
72. Beattie RM, Nicholls SW, Domizio P, et al. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 1996;22:373-9.
73. Berni Canani R, Terrin G, Borelli O, et al. Short and long term efficacy of nutritional therapy and corticosteroids in pediatric Crohn's disease. Dig Liver Dis 2006;38:381-7.
74. Faure C, Andre J, Pelatan C, et al. Pharmacokinetics of intravenous methyl prednisolone and oral prednisolone in paediatric patients with inflammatory bowel disease during the acute phase and in remission. Eur J Clin Pharmacol 1998;54:555-60.
75. Milov DE, Hill M, Andres JM, et al. Measurement of plasma prednisolone level to evaluate a prednisolone treatment failure in an dolescent with Crohn's disease. J Paediatr Gastroenterol Nutr 1989;8:404-7.
76. Tripathi RC, Kipp MA, Tripathi BJ, et al. Occular toxicity of prednisolone n paediatric patients with inflammatory bowel disease. Lens ye Toxicity Res 1992;9:469-82.
77. Tripathi RC, Kirschener BS, Kipp M, et al. Corticosteroid treatment or inflammatory bowel disease in paediatric patients increases ocular ressure. Gastroenterology 1992;102:1957-61.
78. Levine A,Watemberg N, Hager H, et al. Benign intracranial hypertension ssociated with budesonide treatment in children with Crohn's isease. J Child Neurol 2001;16:458-61.
79. Uchida K, Araki T, Toiyama Y, et al. Preoperative steroid-related omplications in Japanese pediatric patients with ulcerative colitis. Dis olon Rectum 2006;49:74-9.
80. Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in childrenwith inflammatory bowel disease: a prospective study. Gastroenterology 993;105:681-91.
81. Azcue M, Rashid M, Griffiths A, et al. Energy expenditure and body omposition with Crohn's disease: effect of enteral nutrition and reatment with prednisolone. Gut 1997;41:203-8.
82. Boot AM, Bouquet J, Krenning EP, et al. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. 1998;42:188-94.
83. Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density ssessment in children with inflammatory bowel disease. Gastroenterology 998;114:902-11.
84. Cowan FJ, Warner JT, Dunstan FD, et al. Inflammatory bowel disease nd predisposition to osteopenia. Arch Dis Child 1997;76:325-9.
85. Walther F, Fusch C, Radke M, et al. Osteoporosis in pediatric patients uffering from chronic inflammatory bowel disease with and without teroid treatment. J Pediatr Gastroenterol Nutr 2006;43:42-51.
86. Kugathasan S, Werlin SL, Martinez A, et al. Prolonged duration of esponse to infliximab in early but not late paediatric Crohn's disease. Am J Gastroenterol 2000;65:3189-94.
87. Mamula P, Markowitz JE, Brown KA, et al. Infliximab as a novel herapy for pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr 002;34:307-11.
88. Cezard JP, Nouaili N, Talbotec C, et al. A prospective study of the fficacy and tolerance of a chimeric antibody to tumor necrosis factors remicade) in severe paediatric Crohn's disease. J Pediatr Gastroenterol utr 2003;36:632-6.
89. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (remicade)therapy in the treatment of paediatric Crohn's disease. Am J Gastroenterol 003;98:833-8.
90. Russell GH, Katz AJ. Infliximab is effective in acute but not chronic hildhood ulcerative colitis. J Pediatr Gastroenterol Nutr 2004;39: 66-70.
91. Borrelli O, Bascietto C, Viola F, et al. Infliximab heals intestinal nflammatory lesions and restores growth in children with Crohn's isease. Dig Liver Dis 2004;36:342-7.
92. de Ridder L, Escher JC, Bouquet J, et al. Infliximab therapy in 30 patients ith refractory pediatric Crohn disease with and without fistulas in the etherlands. J Pediatr Gastroenterol Nutr 2004;39:46-52.
93. Hyams JS, Markowitz J,Wyllie R. Use of infliximab in the treatment of rohn's disease in children and adolescents. J Pediatr 2000;137:192-6.
94. Serrano MS, Schmidt-Sommerfield E, Kilbaugh J, et al. Use of nfliximab in pediatric patients with inflammatory bowel disease. nn Pharmacother 2001;35:823-8.
95. Lionetti P, Bronzini F, Salvestrini C, et al. Response to infliximab is elated to disease duration in paediatric Crohn's disease. Alimentary Pharmacol Ther 2003;18:425-31.
96. Eidelwein AP, Cuffari C, Abadom V, et al. Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 2005;11:213-8.
97. Lamireau T, Cézard JP, Dabadie A, et al. Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2004;10:745-50.
98. Mamula P, Markowitz JF, Cohen LJ, et al. Infliximab in pediatric ulcerative colitis: two-year follow-up. J Pediatr Gastroenterol Nutr 2004;38:298-301.
99. Mian S, Baron H. Adalimumab, a novel anti-tumor necrosis factor-a antibody in a child with refractory Crohn's disease. J Pediatr Gastroenterol Nutr 2005;41:357-9.
100. Schwarzer A, Ricciardelli I, Kirkham S, et al. Management of fulminating ulcerative colitis in childhood with chimeric anti-CD25 antibody. J Pediatr Gastroenterol Nutr 2006;42:245-8.
101. Mamula P, Cohen SA, Ferry GD, et al. CDP571, a humanized antitumor necrosis factor-alpha monoclonal antibody in pediatric Crohn's disease. Inflamm Bowel Dis 2004;10:723-30.
102. Johnson T, MacDonald S, Hill SM, et al. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: arandomised controlled trial. Gut 2006;55:356-61.
103. Akobeng AK, Miller V, Stanton J, et al. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr 2000;30:78-84.
104. Khoshoo V, Reifen R, Neuman MG, et al. Effect of low- and high-fat, peptide-based diets on body composition and disease activity in adolescents with active Crohn's disease. JPEN J Parenter Enteral Nutr 1996;20:401-5.
105. Ludvigsson JF, Krantz M, Bodin L, et al. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized trial. Acta Paediatr 2004;93:327-35.
106. Romano C, Cucchiara S, Barabino A, et al. Usefulness of omega-3 fatty acid supplementation in addition to mesalazine in maintaining remission in pediatric Crohn's disease: a double-blind, randomized, placebo-controlled study. World J Gastroenterol 2005;11:7118-21.
107. Wilschanski N, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996; 38:543-8.
108. Israel DM, Hassall E. Prolonged use of gastrostomy for enteral hyperalimentation in children with Crohn's disease. Am J Gastroenterol 1995;90:1084-8.
109. Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988;94:603-10.
110. Lake AM, Kim S, Mathis RK, et al. Influence of preoperative parenteral alimentation on postoperative growth in adolescent Crohn's disease. J Pediatr Gastroenterol Nutr 1985;4:182-6.
111. Afzal NA, Davies S, Paintin M, et al. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig Dis Sci 2005;50:1471-5.
112. Fell JME, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9.
113. Morin CL, Roluet M, Roy CC, et al. Continuous elemental enteral alimentation in children with Crohn's disease and growth failure. Gastroenterology 1980;79:1205-10.
114. Navarro J, Vargas J, Cezard JP, et al. Prolonged constant rate elemental enteral nutrition in Crohn's disease. J Pediatr Gastroenterol Nutr 1982;1:541-6.
115. Aiges H, Markowitz J, Rosa J, et al. Home nocturnal supplemental naso-gastric feedings in growth-retarded adolescents with Crohn's disease. Gastroenterology 1989;97:905-10.
116. Polk DB, Hattner JAT, Kerner JA Jr. Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohn's disease. JPEN J Parenter Enteral Nutr 1992; 16:499-504.
117. Salvatore S, Heuschkel R, Tomlin S, et al. A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease. Aliment Pharmacol Ther 2000;14:1567-79.
118. Layden T, Rosenberg J, Nemchausky B, et al. Reversal of growth arrest in adolescents with Crohn's disease after parenteral alimentation. Gastroenterology 1976;70:1017-21.
119. Strobel CT, Byrne WJ, Ament ME. Home parenteral nutrition in children with Crohn's disease: an effective management alternative. Gastroenterology 1979;77:272-9.
120. Afzal NA, Addai S, Fagbemi A, et al. Refeeding syndrome with enteral nutrition in children: a case report, literature review and clinical guidelines. Clin Nutr 2002;21:515-20.
121. Pearson DC, May GR, Fick GH, et al. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123: 132-42.
122. Pearson DC, May GR, Fick G, et al. Azathioprine for maintenance of remission in Crohn's disease. Cochrane Database System Rev 1998; 4:CD000067.
123. Sandborn W, Sutherland L, Pearson D, et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database System Rev 1998; 3:CD000545.
124. Alfadhli AAF, McDonald JWD, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database System Rev 2004; 4:CD003459.
125. Shibolet O, Regushevskaya E, Brezis M, et al. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database System Rev 2005; 1:CD004277.
126. McDonald JWD, Feagan BG, Jewell D, et al. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database System Rev 2005; 2:CD000297.
127. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database System Rev 2006; 2:CD000543.
128. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database System Rev 2005; 2:CD000544.
129. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database System Rev 2005; 1:CD003715.
130. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2001; 3:CD000542.
131. Steinhart AH, Ewe K, Griffiths AM, et al. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database System Rev 2003; 4:CD000301.
132. Simms L, Steinhart AH. Budesonide for maintenance of remission in Crohn's disease. Cochrane Database System Rev 2001; 1:CD002913.
133. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7.
134. Rutgeerts P, Van Assche G, Vermeire S. Infliximab therapy for inflammatory bowel disease-seven years on. Aliment Pharmacol Ther 2006;23:451-63.
135. Rosh JR, Gross T, Mamula P, et al. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm Bowel Dis 2007;13:1024-30.
136. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database System Rev 2003; 4:CD003574.
137. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database System Rev 2006; 3:CD005112.
138. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9.
139. Borgaonkar M, MacIntosh D, Fardy J, et al. Anti-tuberculous therapy for maintenance of remission in Crohn's disease. Cochrane Database System Rev 1999; 2:CD000299.
140. Rolfe VE, Fortun PJ, Hawkey CJ, et al. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database System Rev 2006;4:CD004826.
141. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
142. Hyams J, Wilson DC, Thomas A, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 2007;44:185-91.
143. Turner D, Zlotkin SH, Shah PS, et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2007; 2:CD006320.
144. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission of Crohn's disease. Cochrane Database Syst Rev 2007; 1:CD000542.
145. Selby W, Pavali P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007;132:2594-8.
146. Hanauer SB, Sandborne WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33.
147. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007;132:52-65.
148. Newby EA, Sawczenko A, Thomas AG, et al. Interventions for growth failure in childhood Crohn's disease. Cochrane Database System Rev 2005; 3:CD003873.
149. Begg GB, Cho MK, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. JAMA 1996;276:1308-11.
150. Moher D, Schultz KF, Altman D, et al. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;185:1987-91.
151. Glasziou P. Evidence based medicine: does it make a difference? Make it evidence informed practice with a little wisdom. BMJ 2005;330:92.